Treatment and clinical follow-up
| Case | Treatment | Molecular remission* | Plt (×109/L) | Follow-up | Status |
|---|---|---|---|---|---|
| 1 | NA | NA | NA | NA | NA |
| 2 | Nilotinib | No | 385 | 1 month | Alive |
| 3 | Dasatinib | NA | 1043 | 6 months | Alive |
| 4 | Hydroxyurea, then imatinib | No | 368 | 7 months | Alive |
| 5 | Nilotinib | Yes | 340 | 30 months | Alive |
| 6 | Imatinib | Yes | 145 | 32 months | Alive |
| 7 | Imatinib, ruxolitinib | No | 220 | 55 months | Alive |
| 8 | Nilotinib | Yes | 207 | 69 months | Alive |
| 9 | Nilotinib | Yes | 157 | 29 months | Alive |
| 10 | Imatinib | Yes | 205 | 17 months | Alive |
| 11 | Nilotinib | Yes | 262 | 12 months | Alive |
| 12 | Imatinib, UCBT, nilotinib | Yes† | 19 | 48 months | Expired |
*Molecular remission, as determined by quantitative RT-PCR, is defined as levels of BCR-ABL1 transcripts <0.1% on the international scale after the initiation of therapy.
†Initially, then relapsed.
NA, not available; Plt, platelet; UCBT, umbilical cord blood transplant.